<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04980352</url>
  </required_header>
  <id_info>
    <org_study_id>2019-1-12 V1.1</org_study_id>
    <nct_id>NCT04980352</nct_id>
  </id_info>
  <brief_title>Multi-dimensional Signatures for Precisely Predicting the Response and Prognosis of Lung Cancer Patients</brief_title>
  <acronym>Pred-lung</acronym>
  <official_title>Multi-dimensional Signatures for Precisely Predicting the Response and Prognosis of Lung Cancer Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Wuhan Union Hospital, China</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Renmin Hospital of Wuhan University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Wuhan TongJi Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Wuhan University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Wuhan Union Hospital, China</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study aims to determine the clinical effectiveness of multi-dimensional signatures in&#xD;
      predicting response and prognosis of lung cancer patients. The study is a multi-center&#xD;
      perspective research of treatment planning for patients with lung cancer. To characterize&#xD;
      clinical effectiveness, the progression-free survival (PFS) and overall survival (OS) impacts&#xD;
      of multi-dimensional signatures will be estimated.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Multi-dimensional signatures, including NGS-based genotyping, and other essential detections&#xD;
      such as immunohistochemistry (IHC), provides an opportunity to improve outcomes for patients&#xD;
      by tailoring treatments to each individual's genomic profile. This is a multi-center single&#xD;
      arm research study integrating multi-dimensional signatures into clinical decision-making for&#xD;
      patients with lung cancer. The clinical effectiveness of multi-dimensional signatures is&#xD;
      unknown in the real-world of clinics. To identify a counterfactual for Pred-lung approach,&#xD;
      matching methods combined with administrative healthcare data will be used. The survival&#xD;
      impacts of Pred-lung approach compared to usual care in matched controls will then be&#xD;
      estimated.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 1, 2021</start_date>
  <completion_date type="Anticipated">December 30, 2024</completion_date>
  <primary_completion_date type="Anticipated">December 30, 2023</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>PFS</measure>
    <time_frame>through study completion, an average of 6 months</time_frame>
    <description>Progression-free survival</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>OS</measure>
    <time_frame>through study completion, an average of 1 year</time_frame>
    <description>Overall survival</description>
  </secondary_outcome>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Response</condition>
  <condition>Prognosis</condition>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>real world treatment by doctors</intervention_name>
    <description>real world treatment by doctors</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with locally-advanced or metastasis lung cancer&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients with locally-advanced or metastasis lung cancer&#xD;
&#xD;
          -  Life expectancy &gt; 3 months&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Age at diagnosis &lt;18&#xD;
&#xD;
          -  refuse to enroll&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Yuan Li, Dr.</last_name>
    <phone>+862788041911</phone>
    <email>liyuanpumc@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Wuhan Union Hospital</name>
      <address>
        <city>Wuhan</city>
        <state>Hubei</state>
        <zip>430000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sufei Wang, Dr.</last_name>
      <phone>+862783691785</phone>
      <email>wangsufei0@163.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>July 11, 2021</study_first_submitted>
  <study_first_submitted_qc>July 26, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">July 28, 2021</study_first_posted>
  <last_update_submitted>July 26, 2021</last_update_submitted>
  <last_update_submitted_qc>July 26, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 28, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Multi-dimensional Signatures</keyword>
  <keyword>NGS</keyword>
  <keyword>Lung Cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
    <ipd_description>Individual participant data (IPD) are available upon reasonable requests.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

